Search Results - "Nadia, Harbeck"

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer by Harbeck, Nadia

“…The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) early breast cancer (EBC) as recently demonstrated…”
Get full text

Breast cancer is a systemic disease optimally treated by a multidisciplinary team by Harbeck, Nadia

“…Summarizing a vast body of literature without losing meaningful information is a huge task, but the field — and patients — can benefit from these projects…”
Get full text

Palbociclib and Letrozole in Advanced Breast Cancer by Finn, Richard S, Martin, Miguel, Rugo, Hope S, Jones, Stephen, Im, Seock-Ah, Gelmon, Karen, Harbeck, Nadia, Lipatov, Oleg N, Walshe, Janice M, Moulder, Stacy, Gauthier, Eric, Lu, Dongrui R, Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J

“…Among women with previously untreated hormone-receptor–positive advanced breast cancer, the addition of the cyclin-dependent kinase inhibitor palbociclib to…”
Get full text

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer by Turner, Nicholas C, Ro, Jungsil, André, Fabrice, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, Huang Bartlett, Cynthia, Zhang, Ke, Giorgetti, Carla, Randolph, Sophia, Koehler, Maria, Cristofanilli, Massimo

“…In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with…”
Get full text

Neoadjuvant Therapy for HER2-positive Breast Cancer by Wuerstlein, Rachel, Harbeck, Nadia

“…In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard…”
Get more information

Pembrolizumab for Early Triple-Negative Breast Cancer by Schmid, Peter, Cortes, Javier, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Bergh, Jonas, Denkert, Carsten, Park, Yeon Hee, Hui, Rina, Harbeck, Nadia, Takahashi, Masato, Foukakis, Theodoros, Fasching, Peter A, Cardoso, Fatima, Untch, Michael, Jia, Liyi, Karantza, Vassiliki, Zhao, Jing, Aktan, Gursel, Dent, Rebecca, O’Shaughnessy, Joyce

“…The addition of pembrolizumab to platinum-based neoadjuvant chemotherapy significantly increased the percentage of patients with a pathological complete…”
Get full text

Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring by Huber, Marinus, Kepesidis, Kosmas V., Voronina, Liudmila, Božić, Maša, Trubetskov, Michael, Harbeck, Nadia, Krausz, Ferenc, Žigman, Mihaela

“…Health state transitions are reflected in characteristic changes in the molecular composition of biofluids. Detecting these changes in parallel, across a broad…”
Get full text

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer by Im, Seock-Ah, Lu, Yen-Shen, Bardia, Aditya, Harbeck, Nadia, Colleoni, Marco, Franke, Fabio, Chow, Louis, Sohn, Joohyuk, Lee, Keun-Seok, Campos-Gomez, Saul, Villanueva-Vazquez, Rafael, Jung, Kyung-Hae, Chakravartty, Arunava, Hughes, Gareth, Gounaris, Ioannis, Rodriguez-Lorenc, Karen, Taran, Tetiana, Hurvitz, Sara, Tripathy, Debu

“…The addition of ribociclib to hormone therapy showed a greater benefit with regard to overall survival than hormone therapy alone in women with…”
Get full text

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer by Turner, Nicholas C, Slamon, Dennis J, Ro, Jungsil, Bondarenko, Igor, Im, Seock-Ah, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, André, Fabrice, Puyana Theall, Kathy, Huang, Xin, Giorgetti, Carla, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…The addition of palbociclib to fulvestrant prolonged overall survival among women with hormone receptor–positive, HER2-negative advanced breast cancer who had…”
Get full text

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer by Turner, Nicholas C, Liu, Yuan, Zhu, Zhou, Loi, Sherene, Colleoni, Marco, Loibl, Sibylle, DeMichele, Angela, Harbeck, Nadia, André, Fabrice, Bayar, Mohamed Amine, Michiels, Stefan, Zhang, Zhe, Giorgetti, Carla, Arnedos, Monica, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. The…”
Get full text

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment by Gnant, Michael, Harbeck, Nadia, Thomssen, Christoph

“…For the second time, the St. Gallen Consensus Conference on early breast cancer treatment standards took place in Vienna, Austria, where it will remain for the…”
Get full text

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial by Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof

“…Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant…”
Get full text

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies by Duffy, Michael J, McGowan, Patricia M, Harbeck, Nadia, Thomssen, Christoph, Schmitt, Manfred

“…Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen…”
Get full text

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment by Balic, Marija, Thomssen, Christoph, Würstlein, Rachel, Gnant, Michael, Harbeck, Nadia

“…This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the…”
Get full text

Truly personalized therapy — an end to the era of one size fits all by Harbeck, Nadia, Wuerstlein, Rachel

“…In 2018, several trials in breast cancer have shown efficacy of strategies that rely on novel markers, including gene expression assays or pathological…”
Get full text

Clinical validity and clinical utility of Ki67 in early breast cancer by Kreipe, Hans, Harbeck, Nadia, Christgen, Matthias

“…Ki67 represents an immunohistochemical nuclear localized marker that is widely used in surgical pathology. Nuclear immunoreactivity for Ki67 indicates that…”
Get full text

CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib by Eggersmann, Tanja K., Degenhardt, Tom, Gluz, Oleg, Wuerstlein, Rachel, Harbeck, Nadia

“…The majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease. For this subgroup, endocrine therapy is the…”
Get full text

Enhancing global access to cancer medicines by Cortes, Javier, Perez‐García, Jose Manuel, Llombart‐Cussac, Antonio, Curigliano, Giuseppe, El Saghir, Nagi S., Cardoso, Fatima, Barrios, Carlos H., Wagle, Shama, Roman, Javier, Harbeck, Nadia, Eniu, Alexandru, Kaufman, Peter A., Tabernero, Josep, García‐Estévez, Laura, Schmid, Peter, Arribas, Joaquín

“…Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency…”
Get full text

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study by Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

“…The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the…”
Get full text

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? by Harbeck, Nadia

Get full text